Drug Trial Radar · NCT07715136
BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy
Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Mar 20, 2025
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- iCell Gene TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jul 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This single-arm, open-label, phase I trial evaluates the safety and tolerability of ICG318 CAR-T (BCMA-CD19-IL-15/IL15sushi cCAR T cells) in patients with refractory Idiopathic inflammatory myopathy (IIM).
Conditions
- Inflammatory Myopathy
Interventions
ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR-TBiological
Anti-BCMA, Anti-CD19 Compound CAR-T cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Adverse Events (AEs) after ICG318 CAR-T infusion.Time frame: Starting day 0 and up to 2 years after ICG318 CAR-T infusion.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital, Sichuan University
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.